LatticePoint Team

Experts in Access

We have over 40 years of finding solutions for companies like you.

Sean Robbins

Sean Robbins

Managing Partner, LatticePoint

Sean has more than 15 years of experience in pricing and reimbursement while at Amgen.
He has launched several products globally; and developed pricing and market access strategies for pharmaceutical products across the lifecycle. He has been a thought leader in developing strategies and tactics to combat International Reference Pricing; and providing advice to companies about what they can do to better prepare for reference pricing.  He is the author of several publications in clinical and health economics journals and has been involved in the development of pricing defense strategies for several of the early Biosimilars launched in Europe. He was an early advocate in instituting value-based selling programs to bring pricing and Key Account Management teams closer together to foster shared goals in pricing execution.  Sean is currently an Adjunct Assistant Professor at the University of Southern California in the Titus School of Pharmacy and Health Policy. Sean is passionate about introducing profit enhancing pricing analytics and decision tools into pharmaceutical and medical device companies to help drive improvements in company’s bottom line.

Ted Haack

Ted Haack

Vice President

Ted joined LatticePoint in July 2016 and provides advisory services to early-stage companies in the cell and gene therapy space and has advised on market access, EMA Adaptive Pathways, international expansion, talent acquisition, and key customer relationships. Prior to consulting, he spent 17 years working in the pharmaceutical industry and headed the Market Access function for Genzyme’s Rare Disease Business Unit and Pfizer’s Head of Head of Market Access, Primary Care BU. Before joining Pfizer, he spent 7 years at Schering-Plough in various regional and affiliate finance roles. Ted began his career at Deloitte & Touche, including two years in Frankfurt, Germany and is a qualified SEC Audit Committee Financial Expert. He was appointed as an Independent Director of Promethera Biosciences (BE) in April 2019. He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.
Cédric Lecureuil

Cédric Lecureuil

Chief Operating Officer

Cédric joined LatticePoint in September 2014. For more than three years, he was previously a venture capital associate at Omnes Capital, where he has been actively involved in several investments (Gecko Biomedical, Enterome Biosciences, Pixium Vision, SpineGuard). He holds a PhD in Immunology from Paris VI University during which he managed fundamental research on the interplay between chemokine receptors expressed on T cells and the HIV pathophysiology. He holds also an Advanced Master in Strategy and Management of International Business from the ESSEC Business School. Cédric started his career as an advisor in Innovation Management at Innovaction, a Paris based consulting firm. From 2009 to 2011, Cédric was analyst in the Life Sciences team at Ventech, a venture capital firm.

Natali Pennese

Natali Pennese

Senior Consultant Market Access & Pricing

Natali joined LatticePoint in December 2016. She has supported several market access strategy projects, mainly through the development of systematic literature reviews and value communication tools for different European healthcare systems. As a native Spanish speaker, she has also written reimbursement dossiers for Spanish HTA agencies. Natali has also participated in the evaluation of market growth and in-licensing opportunities through epidemiology-based revenue forecasting and potential pricing assessments. During her tenure as consultant at LatticePoint, she has become knowledgeable in various disease areas, and her passion to ensure patient access to personalized and innovative medicines has recently led her to focus on the market access, reimbursement, and cross-border healthcare challenges for cell and gene therapies.

Natali is a biologist holding a PhD in molecular life sciences from the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland. During her academic career, she contributed to several scientific publications in the fields of immunology and epigenetics, and gathered extensive laboratory experience working with stem cells and viral delivery systems that today are being used for human gene therapy. After her PhD, she helped to spin off a business idea about personalized medicine based on fundamental research made on human stem cells at EPFL.

Andrea Zaffalon

Andrea Zaffalon

Senior Consultant Market Access & Pricing

Andrea joined Latticepoint in July 2019. Prior to LatticePoint, he was for 2 years at Debiopharm International S.A. as a Scientist to support the development of new medicines in the oncology and infectious diseases areas.

Andrea holds a PhD in Molecular Life Sciences as well as a M. Sc. In Life Sciences and Technology from the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland. During his scientific career, he worked in the fields of epithelial stem cells biology, molecular biology and human gene therapy in laboratories at EPFL and the Department of Ophthalmology from Kyoto Prefectural University of Medicine (Kyoto, Japan).

Karin Steinbach

Karin Steinbach

Senior Consultant Market Access & Pricing

Karin joined LatticePoint in August 2019. She holds a PhD in Biology obtained from the University of Hamburg, Germany.

Prior to consulting, Karin performed fundamental and translational research in the fields of infectious, autoimmune and neurodegenerative diseases. During her scientific career, she led several research projects, including the development of new animal models for autoimmune diseases and research of new strategies to prevent viral infections. Her research contributed to the identification of new drug targets for the treatment of multiple sclerosis, which are now in development. She has contributed to patent applications, obtained prestigious awards for her research and authored several high-impact publications.

Heinz Straessle

Heinz Straessle

Consultant Market Access & Pricing

Heinz joined LatticePoint in January 2016. He is responsible for the retained payer panel database with a large collection of key stakeholders ranging from payers, prescribers, HTA advisors to medical key opinion leaders in US, Europe and parts of Asia. He focuses on the Market Access and Reimbursement system of the German speaking countries and has hands-on experience with AMNOG reimbursement dossiers and AMNOG exemption for inpatient products. He is also responsible for the pricing database and has conducted several pricing assessments projects as well as developed market forecast Excel models based on epidemiology or market sales.

Heinz received his M.Sc. in Bioengineering from the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland. During his studies, he was working on various academic projects covering subjects from computational molecular biology, development biology, diabetes to biomaterials, stem cells and radiology

Bárbara Magalhães

Bárbara Magalhães

Research Associate

Bárbara joined LatticePoint in July 2019. She has a PhD in Life Sciences (Microbial Sciences Program) from the University of Lausanne, Switzerland.

Her academic background ranged from biochemistry to microbiology where she acquired specialized experience in molecular typing, epidemiology, and bioinformatics. As part of her PhD, she defined and implemented bioinformatic pipelines for real-time outbreak investigation of nosocomial pathogens at the University Hospital of Lausanne, Switzerland, and contributed to several projects on the comparison of different whole genome sequencing analysis approaches, with the outcome of several scientific publications. Through translational research, she was involved in the application of infection control measures in intensive care units.

Ela Szulc

Ela Szulc

Research Associate

Ela joined LatticePoint in March 2020. She holds a PhD in Biomedicine from the University of Barcelona, Spain.

Her background is a combination of biotechnology, biochemistry and structural biology. During her PhD she focused on understanding the relationship between sequence, structure and function in intrinsically disordered proteins. Her research set the basis for investigation of new methods for targeting the disordered domain of androgen receptor, a driver of prostate cancer. During her academic career she has obtained numerous fellowships and authored several publications.

Cristina Freire Sanz

Cristina Freire Sanz

Research Associate

Cristina joined LatticePoint in November 2020. She holds a PhD in Life Sciences from the University of Geneva (Switzerland), and a Master of Science in Bioengineering from Trinity College Dublin (Ireland).

During her scientific career she acquired extensive experience in genetic engineering, molecular biology and regenerative medicine at the University of Geneva, the NYU Langone Medical Center (New York, US) and the Center for Biomedical Engineering (Dublin, Ireland). Over her years of PhD, she carried out different projects including the development of animal models to model rare congenital bleeding disorders using genome editing CRISPR/Cas9 technology. She obtained several awards during her studies and she is author of scientific publications. Apart from her scientific background she holds an MBA specialized in Biotech Companies.

Efe Erdeş

Efe Erdeş

Research Associate

Efe joined LatticePoint in June 2021. He holds a PhD in Life Sciences (Cancer and Immunology) from the University of Lausanne (Switzerland), and a Master of Science in Biotechnology from Middle East Technical University (Ankara, Turkey).

Before moving into the consulting sector, he was specialized in tumor immunology research with an emphasis on T cell-based cellular therapies. He contributed to the development and the optimization of adoptive cell transfer strategies with the use of T cell receptor affinity-engineered CD8 T cells against malignant skin cancers. His projects aimed to better understand the molecular interactions and the intracellular pathways leading to tumor antigen-specific T cell activation to eventually augment patients’ benefits from the therapy, while minimizing the risks and the adverse events. Due to his scientific background, he is expertized and interested in immunology, oncology, cellular biology and protein biochemistry domains.

We have a multilingual staff of native German, French, Italian, Spanish, Portuguese, Polish and English speakers who have negotiated on behalf of our clients. A quality that is unique in the industry; that’s what we do.